Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Amedisys ( (AMED) ) is now available.
On August 14, 2025, Amedisys completed a merger that led to significant changes in its financial and operational structure. The company terminated its existing credit agreement, paid off its outstanding obligations, and delisted its common stock from Nasdaq. The merger also resulted in the conversion of equity awards and the resignation of the board of directors, marking a substantial shift in the company’s governance and shareholder rights.
The most recent analyst rating on (AMED) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Amedisys stock, see the AMED Stock Forecast page.
Spark’s Take on AMED Stock
According to Spark, TipRanks’ AI Analyst, AMED is a Outperform.
Amedisys exhibits strong financial performance and positive corporate developments, such as the pending merger with UnitedHealth Group. However, the high P/E ratio suggests potential overvaluation, and the absence of dividend yield limits income attractiveness. Technical indicators show a bullish trend, supporting a positive outlook.
To see Spark’s full report on AMED stock, click here.
More about Amedisys
Amedisys is a company involved in the healthcare industry, primarily providing home health care and hospice services. The company focuses on delivering personalized health care services to patients in their homes, aiming to improve patient outcomes and reduce healthcare costs.
Average Trading Volume: 498,270
Technical Sentiment Signal: Hold
Current Market Cap: $3.32B
For detailed information about AMED stock, go to TipRanks’ Stock Analysis page.